Therapeutic Asset Ratings

388 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Psma-Hbed-Cc Recurrence	Novartis Pharmaceuticals	P3	B (62)
Solu-Cortef B Acute Lymphoblastic Leukemia, BCR-ABL1-Like	Novartis Pharmaceuticals	P3	B (62)
Votoplam Huntington Disease	Novartis Pharmaceuticals	P3	B (62)
Asciminib Leukemia, Lymphoblastic, Acute, Philadelphia-Positive	Novartis Pharmaceuticals	P2	B (62)
Onfasprodil Depressive Disorder, Treatment-Resistant	Novartis Pharmaceuticals	P2	B (62)
PIFLUFOLASTAT Prostatic Neoplasms	Novartis Pharmaceuticals	P2/3	B (62)
Epirubicin Acute Coronary Syndrome	Novartis Pharmaceuticals	P4	B (61)
gsk1120212 Neurofibromatosis Type 1	Novartis Pharmaceuticals	P4	B (61)
gsk1120212 Rare Cancers	Novartis Pharmaceuticals	P4	B (61)
Panobinostat Polycythemia Vera	Novartis Pharmaceuticals	P4	B (61)
Panobinostat Thalassemia	Novartis Pharmaceuticals	P4	B (61)
Pembrolizumab Acute Coronary Syndrome	Novartis Pharmaceuticals	P4	B (61)
Dabrafenib Neurofibromatosis Type 1	Novartis Pharmaceuticals	P4	B (60)
Dabrafenib Rare Cancers	Novartis Pharmaceuticals	P4	B (60)
Panobinostat Graft Versus Host Disease	Novartis Pharmaceuticals	P4	B (60)
Inclisiran Acute Coronary Syndrome	Novartis Pharmaceuticals	P3	B (60)
Inclisiran Atherosclerotic Cardiovascular Disease	Novartis Pharmaceuticals	P3	B (60)
NON-REPLICATING RECOMBINANT SELF-COMPLEMENTARY (SC) ADENO-ASSOCIATED VIRUS SEROTYPE 9 (AAV9) VECTOR CONTAINING THE CDNA OF THE SURVIVAL OF MOTOR NEURON 2 (SMN2) GENE UNDER THE CONTROL OF THE HYBRID CYTOMEGALOVIRUS (CMV) ENHANCER/CHICKEN BETA-ACTIN PROMOTER (CBA) Spinal Muscular Atrophies	Novartis Pharmaceuticals	P3	B (60)
PCV 13 Multiple Sclerosis, Relapsing-Remitting	Novartis Pharmaceuticals	P3	B (60)
tqj230 Cardiovascular Disease and Lipoprotein(a)	Novartis Pharmaceuticals	P3	B (60)
IMMUNOGLOBULIN G1, ANTI-(HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR TYPE VEGFR-2 EXTRACELLULAR DOMAIN) (HUMAN MONOCLONAL IMC-1121B .GAMMA.-CHAIN), DISULPHIDE WITH HUMAN MONOCLONAL IMC-1121B .KAPPA.-CHAIN, DIMER Renal Cell Carcinoma	Novartis Pharmaceuticals	P2	B (60)
Letrozole Locally Advanced or Metastatic Castration-resistant Prostate Cancer	Novartis Pharmaceuticals	P2	B (60)
Oxodotreotide Metastatic Neuroendocrine Prostate Cancer	Novartis Pharmaceuticals	P2	B (60)
Pelacarsen Cardiovascular Disease and Lipoprotein(a)	Novartis Pharmaceuticals	P3	B (59)
Tisagenlecleucel Follicular Lymphoma	Novartis Pharmaceuticals	P3	B (59)

Showing 76 to 100 of 388 assets

PreviousPage 4 of 16Next